Trade Theravance Biopharma, Inc. - TBPH CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 9.16 |
| Open | 9.16 |
| 1-Year Change | 6.39% |
| Day's Range | 9.11 - 9.44 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 18, 2025 | 9.16 | -0.07 | -0.76% | 9.23 | 9.47 | 9.16 |
| Mar 17, 2025 | 9.33 | 0.31 | 3.44% | 9.02 | 9.41 | 8.96 |
| Mar 14, 2025 | 9.19 | 0.15 | 1.66% | 9.04 | 9.34 | 9.04 |
| Mar 13, 2025 | 9.25 | -0.04 | -0.43% | 9.29 | 9.34 | 9.03 |
| Mar 12, 2025 | 9.39 | 0.24 | 2.62% | 9.15 | 9.45 | 9.04 |
| Mar 11, 2025 | 9.27 | -0.02 | -0.22% | 9.29 | 9.41 | 9.09 |
| Mar 10, 2025 | 9.43 | 0.17 | 1.84% | 9.26 | 9.48 | 9.26 |
| Mar 7, 2025 | 9.51 | 0.04 | 0.42% | 9.47 | 9.83 | 9.38 |
| Mar 6, 2025 | 9.69 | 0.39 | 4.19% | 9.30 | 9.85 | 9.30 |
| Mar 5, 2025 | 9.69 | 0.68 | 7.55% | 9.01 | 9.77 | 9.00 |
| Mar 4, 2025 | 9.08 | 0.13 | 1.45% | 8.95 | 9.18 | 8.93 |
| Mar 3, 2025 | 9.12 | -0.11 | -1.19% | 9.23 | 9.33 | 9.03 |
| Feb 28, 2025 | 9.14 | -0.03 | -0.33% | 9.17 | 9.48 | 9.06 |
| Feb 27, 2025 | 9.24 | -0.34 | -3.55% | 9.58 | 10.09 | 8.97 |
| Feb 26, 2025 | 9.04 | 0.24 | 2.73% | 8.80 | 9.07 | 8.80 |
| Feb 25, 2025 | 8.94 | 0.17 | 1.94% | 8.77 | 9.12 | 8.68 |
| Feb 24, 2025 | 8.80 | -0.40 | -4.35% | 9.20 | 9.31 | 8.80 |
| Feb 21, 2025 | 9.26 | -0.27 | -2.83% | 9.53 | 9.64 | 9.23 |
| Feb 20, 2025 | 9.63 | 0.20 | 2.12% | 9.43 | 10.00 | 9.43 |
| Feb 19, 2025 | 9.71 | 0.26 | 2.75% | 9.45 | 9.72 | 9.41 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Theravance Biopharma, Inc. Company profile
About Theravance Biopharma Inc
Theravance Biopharma, Inc. is a diversified biopharmaceutical company, which is primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicines to improve the lives of patients suffering from serious illnesses. The Company's research is focused in the areas of inflammation and immunology. It applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The Company is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Theravance Biopharma Inc revenues decreased 23% to $55.3M. Net loss decreased 28% to $199.4M. Revenues reflect U.S. segment decrease of 21% to $55.3M, Europe segment decrease of 98% to $38K. Lower net loss reflects Research and development - bal decrease of 27% to $166.6M (expense), Selling, general and administrative -bal decrease of 55% to $31M (expense).
| Industry: | Pharmaceuticals (NEC) |
Ugland House, South Church Street
GEORGE TOWN
GRAND CAYMAN KY1-1104
KY
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 700,000+ traders worldwide that chose to trade with Capital.com